Oppenheimer Downgrades PLx Pharma to Perform
Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
Applied Industrial Technologies Gets Price Target Hike Following Q4 Results
KeyBanc analyst Ken Newman raised the price target for Applied Industrial Technologies Inc (NYSE:AIT) to $140 from $120 while maintaining the Overweight ratings…
Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming ‘Pipeline Reset’
Raymond James downgraded Landos Biopharma Inc (NASDAQ:LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13…
Why This Cognex Analyst Is No Longer Bullish
Temporary setbacks in inventory loss, project deferrals in logistics, and FX/component costs headwinds are weighing on Cognex Corporation’s (NASDAQ: CGNX) short term success since it is mostly a book and ship business, according to a JPMorgan analyst.
JP Morgan Downgrades ResMed to Neutral
JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.
B of A Securities Downgrades Cellebrite DI to Neutral, Lowers Price Target to $6
B of A Securities analyst Tal Liani downgrades Cellebrite DI (NASDAQ:CLBT) from Buy to Neutral and lowers the price target from $6.5 to $6.
Why This CS Disco Analyst Is Downgrading Legal Services Stock After Q2 Earnings
CS Disco Inc (NYSE: LAW) reported mixed results for its second quarter, with revenues below Street estimates and higher-than-expected EBITDA.
4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment
4D Molecular Therapeutics Inc (NASDAQ:FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing…
Sidoti & Co. Downgrades Co-Diagnostics to Neutral, Announces $5 Price Target
Sidoti & Co. analyst James Sidoti downgrades Co-Diagnostics (NASDAQ:CODX) from Buy to Neutral and announces $5 price target.
RBC Capital Downgrades ResMed to Sector Perform, Raises Price Target to $252
RBC Capital analyst Craig Wong-Pan downgrades ResMed (NYSE:RMD) from Outperform to Sector Perform and raises the price target from $246 to $252.